Related Experiment Videos
Intravesical therapy for superficial bladder cancer
1University of Pennsylvania Medical Center, Philadelphia, USA.
Seminars in Urologic Oncology
|December 2, 2000
Summary
Intravesical Bacillus Calmette-Guerin (BCG) is effective for bladder cancer but poorly tolerated. Newer strategies, including interferon and single-dose chemotherapy, aim to improve treatment tolerability and reduce early tumor recurrence.
Area of Science:
- Urology
- Oncology
- Cancer Research
Background:
- Intravesical therapy is a standard treatment for superficial bladder cancer.
- Bacillus Calmette-Guerin (BCG) is the most effective agent for carcinoma in situ.
- Current BCG regimens can be poorly tolerated by patients.
Purpose of the Study:
- To explore novel intravesical therapies for superficial bladder cancer.
- To evaluate the potential of intravesical interferon in combination with BCG.
- To assess the efficacy of single-dose intravesical chemotherapy in reducing early tumor recurrence.
Main Methods:
- Review of recent clinical data and studies on intravesical therapies.
- Analysis of treatment outcomes for BCG, interferon, and chemotherapy regimens.
- Evaluation of recurrence and progression rates in superficial bladder cancer patients.
Main Results:
- Booster BCG treatments show benefits over 3 years but are often not well-tolerated.
- Intravesical interferon may enhance BCG efficacy.
- Intravesical chemotherapy reduces tumor recurrence by 14-17% but not progression.
- A growing rationale exists for single-dose intravesical chemotherapy to decrease early recurrence.
Conclusions:
- Optimizing intravesical therapy for superficial bladder cancer is crucial.
- Investigating combinations like BCG with interferon and single-dose chemotherapy warrants further research.
- Reducing early tumor recurrence through improved intravesical strategies is a key objective.